Cargando…
Vaccination and Transmission Risk during the Outbreak of B.1.1.529 (Omicron)
Since its first description in November 2021, the SARS-CoV-2 variant of concern Omicron (B.1.1.529) has emerged as the dominant strain in the COVID-19 pandemic. To date, it remains unclear if boosted vaccination protects against transmission. Using data from the largest German Public Health Departme...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322361/ https://www.ncbi.nlm.nih.gov/pubmed/35891167 http://dx.doi.org/10.3390/vaccines10071003 |
_version_ | 1784756284303605760 |
---|---|
author | Grüne, Barbara Grüne, Jakob Kossow, Annelene Joisten, Christine |
author_facet | Grüne, Barbara Grüne, Jakob Kossow, Annelene Joisten, Christine |
author_sort | Grüne, Barbara |
collection | PubMed |
description | Since its first description in November 2021, the SARS-CoV-2 variant of concern Omicron (B.1.1.529) has emerged as the dominant strain in the COVID-19 pandemic. To date, it remains unclear if boosted vaccination protects against transmission. Using data from the largest German Public Health Department, Cologne, we analyzed breakthrough infections in booster-vaccinated infected persons (IP; booster-vaccinated group (BVG); n = 202) and fully vaccinated, not boosted SARS-COV2-positive patients (>3 month after receiving the second dose; unboosted, fully vaccinated group (FVG); n = 202) to close contacts compared to an age- and sex-matched unvaccinated control group (UCG; n = 202). On average, IPs had 0.42 ± 0.52 infected contacts in relation to the total number of contacts in the BVG vs. 0.57 ± 0.44 in the FVG vs. 0.56 ± 0.43 in the UVG (p = 0.054). In the median test, pairwise comparison revealed a significant difference between the BVG and both other groups; no difference was found between the fully vaccinated and the unvaccinated control group. Now, these findings must be verified in larger samples, considering the role of Omicron subvariants and the vaccination status of the contact person. However, the importance of the booster vaccination in breaking possible chains of infection in the immune escape variant Omicron is obvious. |
format | Online Article Text |
id | pubmed-9322361 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93223612022-07-27 Vaccination and Transmission Risk during the Outbreak of B.1.1.529 (Omicron) Grüne, Barbara Grüne, Jakob Kossow, Annelene Joisten, Christine Vaccines (Basel) Communication Since its first description in November 2021, the SARS-CoV-2 variant of concern Omicron (B.1.1.529) has emerged as the dominant strain in the COVID-19 pandemic. To date, it remains unclear if boosted vaccination protects against transmission. Using data from the largest German Public Health Department, Cologne, we analyzed breakthrough infections in booster-vaccinated infected persons (IP; booster-vaccinated group (BVG); n = 202) and fully vaccinated, not boosted SARS-COV2-positive patients (>3 month after receiving the second dose; unboosted, fully vaccinated group (FVG); n = 202) to close contacts compared to an age- and sex-matched unvaccinated control group (UCG; n = 202). On average, IPs had 0.42 ± 0.52 infected contacts in relation to the total number of contacts in the BVG vs. 0.57 ± 0.44 in the FVG vs. 0.56 ± 0.43 in the UVG (p = 0.054). In the median test, pairwise comparison revealed a significant difference between the BVG and both other groups; no difference was found between the fully vaccinated and the unvaccinated control group. Now, these findings must be verified in larger samples, considering the role of Omicron subvariants and the vaccination status of the contact person. However, the importance of the booster vaccination in breaking possible chains of infection in the immune escape variant Omicron is obvious. MDPI 2022-06-23 /pmc/articles/PMC9322361/ /pubmed/35891167 http://dx.doi.org/10.3390/vaccines10071003 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Grüne, Barbara Grüne, Jakob Kossow, Annelene Joisten, Christine Vaccination and Transmission Risk during the Outbreak of B.1.1.529 (Omicron) |
title | Vaccination and Transmission Risk during the Outbreak of B.1.1.529 (Omicron) |
title_full | Vaccination and Transmission Risk during the Outbreak of B.1.1.529 (Omicron) |
title_fullStr | Vaccination and Transmission Risk during the Outbreak of B.1.1.529 (Omicron) |
title_full_unstemmed | Vaccination and Transmission Risk during the Outbreak of B.1.1.529 (Omicron) |
title_short | Vaccination and Transmission Risk during the Outbreak of B.1.1.529 (Omicron) |
title_sort | vaccination and transmission risk during the outbreak of b.1.1.529 (omicron) |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322361/ https://www.ncbi.nlm.nih.gov/pubmed/35891167 http://dx.doi.org/10.3390/vaccines10071003 |
work_keys_str_mv | AT grunebarbara vaccinationandtransmissionriskduringtheoutbreakofb11529omicron AT grunejakob vaccinationandtransmissionriskduringtheoutbreakofb11529omicron AT kossowannelene vaccinationandtransmissionriskduringtheoutbreakofb11529omicron AT joistenchristine vaccinationandtransmissionriskduringtheoutbreakofb11529omicron |